Back to Search Start Over

IGF-IEc expression is increased in secondary compared to primary foci in neuroendocrine neoplasms.

Authors :
Alexandraki KI
Philippou A
Boutzios G
Theohari I
Koutsilieris M
Delladetsima IK
Kaltsas GA
Source :
Oncotarget [Oncotarget] 2017 Sep 08; Vol. 8 (45), pp. 79003-79011. Date of Electronic Publication: 2017 Sep 08 (Print Publication: 2017).
Publication Year :
2017

Abstract

Different Insulin-like growth factor-I (IGF-I) mRNA transcripts are produced by alternative splicing and particularly the IGF-IEc isoform has been implicated in the development and/or progression of various types of cancer. In the present study, we examined the potential role of IGF-IEc expression as a new immunohistochemical marker of aggressiveness in neuroendocrine neoplasms (NENs). We utilized immunohistochemical analysis in tissue specimens of 47 patients with NENs, to evaluate the expression of IGF-IEc (%) and Ki-67 proliferation index (%). Specimens from patients with tumors of different tissue origin, of either primary or metastatic lesions and of different grade were examined. Cytoplasmic IGF-IEc staining was found in 23 specimens of NENs or NECs: 10 pancreatic, 4 small bowel, 3 gastric, 1 lung, 1 uterine and 4 poorly differentiated of unknown primary origin. Ki-67 and IGF-IEc expression was positively correlated in all the samples studied (r=0.31, p=0.03). IGF-1Ec expression was more prevalent in specimens originating from metastatic foci with high Ki-67 compared to primary sites with low Ki-67 expression (p=0.036). These findings suggest a possible role of IGF-IEc in NEN tumorigenesis and progression to metastases that could be used as an additional new marker of a more aggressive behavior and a potential drugable target.<br />Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest.

Details

Language :
English
ISSN :
1949-2553
Volume :
8
Issue :
45
Database :
MEDLINE
Journal :
Oncotarget
Publication Type :
Academic Journal
Accession number :
29108282
Full Text :
https://doi.org/10.18632/oncotarget.20743